Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome in db/db Mice

Diabetes

Volumn 53, Issue 2, 2004, Pages 410-417

  Liang, Yin ^a   Osborne, Melville C ^a   Monia, Brett P ^b   Bhanot, Sanjay ^b   Gaarde, William A ^b   Reed, Chantal ^b   She, Pengxiang ^a   Jetton, Thomas L ^c   Demares, Keith T ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP; FATTY ACID; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; MESSENGER RNA; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; LIVER CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD GLUCOSE; CYCLIC AMP; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GLUCONEOGENESIS; HEPATOCYTES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, GLUCAGON; TRANSCRIPTION, GENETIC;

EID: 0842288445     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.2.410     Document Type: Article

References (23)

1. DeFronzo RA: The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
2. Cherrington AD: Banting Lecture 1997: Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214, 1999
3. Boden G, Tappy L, Jadali F, Hoeldtke RD, Rezvani I, Owen OE: Role of glucagon in disposal of an amino acid load. Am J Physiol 259:E225-E232, 1992
4. Pilkis SJ, Granner DK: Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54:885-909, 1992
5. Dobbs R, Sakurai H, Sasaki H, Faloona G, Valverde I, Baetens D, Orci L, Unger R: Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544-547, 1975
6. Unger R, Orci L: The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet i:14-16, 1975
7. Sakurai H, Dobbs R, Unger R: Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs. J Clin Invest 54:1395-1402, 1974
8. Del Prato S, Castellino P, Simonson DC, DeFronzo RA: Hyperglucagonemia and insulin-mediated glucose metabolism. J Clin Invest 79:547-556, 1987
9. Jiang GQ, Zhang BB: Glucagon and regulation of glucose metabolism. Am J Physiol 284:E671-E678, 2003
10. Parker J, Andrews K, Allen M, Stock J, McNeish J: Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839-843, 2002
11. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ: Lower blood glucose, hyperglucagonemia, and pancreatic α-cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438-1443, 2003
12. Amatruda J, Livingston J: The search for glucagon antabonists. In Handbook of Experimental Pharmacology. Lefebvre PJ, Ed. Berlin, Springer, 1996, p. 133-147
13. Ling A, Plewe M, Gonzalez J, Madsen P, Sams CK, Lau J, Gregor V, Murphy D, Teston K, Kuki A, Shi S, Truesdale L, Kiel D, May J, Lakis J, Anderes K, Iatsimirskaia E, Sidelmann UG, Knudsen LB, Brand CL, Polinsky A: Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem 12:663-666, 2002
14. Petersen K, Sullivan J: Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024, 2001
15. Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF, Dean NM, Bhanot S, Monia BP: Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51:1028-1034, 2002
16. Gum R, Gaede L, Koterski S, Heindel M, Clampit J, Zinker B, Trevillyan J, Ulrich R, Jirousek M, Rondinone C: Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52:21-28, 2003
17. Baker B, Lot S, Condon T, Cheng-Flournoy S, Lesnik E, Sasmor H, Bennett C: 2′-O-(2-methoxy)ethyl-modified anti-cellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 272:11994-12000, 1997
18. Graham M, Crooke S, Monteith D, Cooper S, Lemonidis K, Stecker K, Martin M, Crooke R: In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 286:447-458, 1998
19. Dean N, McKay R: Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 91:11762-11766, 1994
20. Vickers T, Koo S, Bennett C, Crroke S, Dean N, Baker B: Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. J Biol Chem 278:7108-7118, 2003
21. Li F, Ackermann E, Bennett C, Rothermel A, Plescia J, Tognin S, Villa A, Marchisio P, Altieri D: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1:461-499, 1999
22. She P, Shiota M, Shelton K, Chalkley R, Postic C, Magnuson M: Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. Mol Cell Biol 20:6508-6517, 2000
23. Hippen A, She P, Young J, Beitz D, Lindberg G, Richardson L, Tucker R: Alleviation of fatty liver in dairy cows with 14-day intravenous infusions of glucagon. J Dairy Sci 82:1139-1152, 1999